Global Kidney Fibrosis Treatment Market Size study & Forecast, by Therapeutics (Angiotensin II receptor blockers (ARBs), Angiotensin Converting Enzyme (ACE) inhibitors, Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors), by End User (hospital, Clini

Global Kidney Fibrosis Treatment Market Size study & Forecast, by Therapeutics (Angiotensin II receptor blockers (ARBs), Angiotensin Converting Enzyme (ACE) inhibitors, Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors), by End User (hospital, Clinics, Home Treatment) and Regional Analysis, 2022-2029

Global Kidney Fibrosis Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Kidney Fibrosis refers to excessive production and deposition of extracellular matrix (ECM) proteins in the kidney interstitium. This excessive production and deposition of ECM causes structural damage, impairment of renal function, and leads to end-stage renal disease (ESRD). Diabetes and Hypertension are two leading causes of Kidney Fibrosis. Apart from these two as infectious glomerulonephritis, renal vasculitis, ureteral obstruction, genetic alterations, and autoimmune diseases among others also causes Kidney Fibrosis. The increasing incidence of chronic kidney diseases and rowing awareness towards renal fibrosis treatment as well as strategic initiatives from leading market player are key factors accelerating the market growth.

According to the Centers for Disease Control & Prevention – as of 2021, around 37 million US individual are affected by chronic kidney diseases, witnessing for over 15% of all US adults. Moreover, as per National Kidney Foundation estimates- in the United States more than 1 in 7 adults are diagnosed with chronic kidney disease. In addition, around 90% of individuals with kidney disease are not aware about their disease. Also, rising number of favorable initiatives from government authorities and increasing prevalence of lifestyle diseases would create lucrative growth prospectus for the market over the forecast period. However, complex process associated with regulatory approvals stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Kidney Fibrosis Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America the leading region in terms of market share owing to increasing prevalence of chronic kidney diseases as well as favorable initiatives from government authorities in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising healthcare spending as well as growing prevalence of lifestyle diseases such as hypertension and diabetes in the region.

Major market player included in this report are:
Merck & Co.
F. Hoffman-La Roche Ltd.
Pfizer Inc.
Galectin Therapeutics
La Jolla Pharmaceutical Company
InterMune Inc.
ProMetic Life-Sciences Inc.
Genzyme Corporation
BioLine Rx Ltd
Certa Therapeutics
Recent Developments in the Market:
In March 2022, Zydus Lifesciences received approval for its New Drug Application (NDA) named Oxemia from the Drug Controller General of India (DCGI). The new drug Oxemia, would be a first-of-its-kind oral treatment in India for anaemia associated with chronic kidney disease (CKD)

In August 2022, Bayer launched a new drug named finerenone for treatment of chronic kidney disease associated with type-2 diabetes in India. This new drug would be sold in India under brand name Kerendia.


In August 2022, USA based Children’s Hospital of Philadelphia (CHOP) and Penn Medicine jointly announced the launch of Penn-CHOP Kidney Innovation Center. This new center would be first-of-its-kind and would work towards advance research for the early detection, prevention, and treatment of kidney disease and its associated complications.


Global Kidney Fibrosis Treatment Market Report Scope:
Historical DataCompanies Mentioned

Merck & Co.
F. Hoffman-La Roche Ltd.
Pfizer Inc.
Galectin Therapeutics
La Jolla Pharmaceutical Company
InterMune Inc.
ProMetic Life-Sciences Inc.
Genzyme Corporation
BioLine Rx Ltd
Certa Therapeutics

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.